Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study | Zendy

Ellen Tedaldi | Zendy; Lars Peters | Zendy; Jacquie Neuhaus | Zendy; Massimo Puoti | Zendy; Jürgen K. Rockstroh | Zendy; Marina B. Klein | Zendy; Gregory J. Dore | Zendy; Amanda Mocroft | Zendy; Vincent Soriano | Zendy; Bonaventura Clotet | Zendy; Jens Lundgren | Zendy

Open Access

Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study

Author(s) -

Ellen Tedaldi,

Lars Peters,

Jacquie Neuhaus,

Massimo Puoti,

Jürgen K. Rockstroh,

Marina B. Klein,

Gregory J. Dore,

Amanda Mocroft,

Vincent Soriano,

Bonaventura Clotet,

Jens Lundgren

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/593102

Subject(s) - medicine , hazard ratio , hepatitis b , hepatitis c , hepatitis c virus , mortality rate , immunology , hepatitis b virus , viral load , confidence interval , gastroenterology , human immunodeficiency virus (hiv) , virus

In the Strategic Management of Antiretroviral Therapy (SMART) study, the risk of opportunistic disease (OD) and/or death due to any cause was elevated in the drug conservation (i.e., interrupt antiretroviral therapy until the CD4(+) cell count is <250 cells/microL) group, compared with the viral suppression (continued use of antiretroviral therapy) group. We assessed whether participants with concurrent hepatitis had an increased risk of the end points evaluated in the SMART study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research